Our Mission

Scientific American LogoOur mission is to save lives and to improve the quality of life by creating and commercializing novel, broad-spectrum biopharmaceuticals to prevent and treat current and emerging life-threatening human diseases.

NexBio is recipient of the 4th Annual “Scientific American 50” Award for a medical treatment. Prior award winners include Genentech, IDEC Pharmaceuticals, and Vertex Pharmaceuticals.
(click icon for press release)
 
Fludase®

fludaseFludase® is in clinical development as a first-in-class broad-spectrum prophylactic and therapeutic agent for Influenza-like Illness caused by all annual and pandemic variations of influenza virus (IFV), including the Avian IFV H5N1, as well as parainfluenza. Fludase® is a receptor inactivator and works by preventing viral entry into cells. Unlike current antivirals, the drug targets human host receptors, not virus components, conferring a low likelihood for the development of resistance.
 

Corporate Profile

ScientistNexBio is a San Diego based company in operation since 2003.  NexBio is the recipient of five NIH grants totaling $14M and a BAA contract for $49.5M.  NexBio’s lead product, Fludase®, is currently undergoing Phase 1 clinical development.  NexBio is performing lead optimization of a second novel protein therapeutic, Viradin™.  NexBio has also invented TOSAP® a proprietary microparticle formulation technology used for its compounds, as well as those of its partners.

Pandemic Influenza

As the world braces for a global influenza pandemic, NexBio feels a strong social responsibility to protect human lives by advancing its anti-influenza medication Fludase® as quickly and safely as possible.

Below is a map provided by the Department of Health and Human Services showing the spread of H5N1 around the world, in humans, poultry, and wild birds.  The avian Influenza strain H5N1, as well as other strains, has a great potential for pandemic outbreak.

pandemic_infl_map